Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy
Sign Up to like & getrecommendations! Published in 2020 at "Drug Design, Development and Therapy"
DOI: 10.2147/dddt.s267433
Abstract: Abstract PD-1/PD-L1 inhibitors are a group of immune checkpoint inhibitors as front-line treatment of multiple types of cancer. However, the serious immune-related adverse reactions limited the clinical application of PD-1/PD-L1 monoclonal antibodies, despite the promising… read more here.
Keywords: therapy; research status; status outlook; therapy research ... See more keywords